Gemcitabine-based adjuvant chemotherapy in subtypes of ampullary adenocarcinoma: international propensity score-matched cohort study.
Alma L MoekotteG MalleoS van RoesselM BondsA HalimiL ZarantonelloN NapoliStephan B DreyerUlrich Friedrich WellnerL BolmV K MavroeidisS RobinsonK KhalilD FerraroM C MortimerS HarrisB Al-SarirehG K FusaiKeith J RobertsM FontanaS A WhiteZ SoonawallaNigel B JamiesonUgo BoggiA AlseidiA ShablakJ W WilminkJ N PrimroseR SalviaC BassiM G BesselinkM Abu HilalPublished in: The British journal of surgery (2020)
Patients with resected ampullary adenocarcinoma may benefit from gemcitabine-based adjuvant chemotherapy, but this effect may be reserved for those with the pancreatobiliary and/or mixed subtype.